OpenAlex
PricingAboutJobs
Log inGet started
Work

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

HTML

Year: 2017
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-16-0712
Authors: Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret, Sirisha Mushti, Kun He, Shawna L. Weis, Alexander H. Putman, Whitney S. Helms, Xianhua Cao, Hongshan Li, Hong Zhao, Liang Zhao, Joel Welch, Laurie Graham, Meredith Libeg, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur
Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: nivolumab, metastatic melanoma, unresectable melanoma, ipilimumab, BRAF V600 mutation, BRAF inhibitors, immune checkpoint inhibitors, objective response rate, accelerated FDA approval, drug approval
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2572843558
FWCI: 7.708
Cites: 5
Cited by: 191
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms